Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
60
-
Total 13F shares, excl. options
-
32.5M
-
Shares change
-
-378K
-
Total reported value, excl. options
-
$8.36M
-
Value change
-
-$118K
-
Put/Call ratio
-
0.02
-
Number of buys
-
28
-
Number of sells
-
-23
-
Price
-
$0.26
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q3 2024
72 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q3 2024.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 60 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.5M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (12.8M shares), CITADEL ADVISORS LLC (4.77M shares), BlackRock, Inc. (2.99M shares), Samsara BioCapital, LLC (2.78M shares), VANGUARD GROUP INC (1.78M shares), Ikarian Capital, LLC (1.06M shares), SEI INVESTMENTS CO (998K shares), GEODE CAPITAL MANAGEMENT, LLC (768K shares), MORGAN STANLEY (652K shares), and GOLDMAN SACHS GROUP INC (547K shares).
This table shows the top 60 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.